Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
ID: 349976Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349976

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-027.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access" (X01), aimed at providing researchers access to critical biospecimens and related data from the PATH Study. This initiative seeks to support studies that align with the objectives of tobacco regulatory science, emphasizing the importance of understanding tobacco use behaviors and health outcomes in the U.S. The PATH Study, which has been collecting longitudinal data since 2011, includes biological samples such as urine, serum, plasma, and genomic DNA. Applications will be accepted starting March 30, 2024, with a final submission deadline of October 31, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-027-Full-Announcement.html
    PAR-24-027.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has announced the funding opportunity titled "Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access" (X01). This initiative allows researchers to access critical biospecimens and related data gathered from the PATH Study, aimed at understanding tobacco use and its health outcomes in the U.S. Initially launched in 2011, the PATH Study collects longitudinal data from a national cohort, which includes biological samples such as urine, serum, plasma, and genomic DNA. The NOFO emphasizes the significance of meritorious studies aligned with PATH objectives in tobacco regulatory science. Applicants must confirm the availability of necessary biospecimens before applying and adhere to detailed application instructions. The funding announcement includes various eligibility requirements for institutions, emphasizing the importance of diversity among applicants. The review process will focus on the scientific merit of proposals, with an expected outcome of advancing public health knowledge and policies regarding tobacco use. The applications will be accepted starting March 30, 2024, with a final due date of October 31, 2026, and there is no direct funding associated with this award mechanism.
    Similar Opportunities
    NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access." This initiative aims to provide researchers with access to biospecimens from significant studies, including the Adolescent Brain Cognitive Development (ABCD) Study and the HEALthy Brain and Child Development (HBCD) Study, to enhance understanding of the genetic and environmental factors influencing health and disease throughout life. The grant is open to a wide range of eligible applicants, including tribal governments, federal agencies, and foreign institutions, with no cost-sharing requirement. Interested parties should note that the estimated award date is January 4, 2027, and they can reach out to Heather L. Kimmel at heather.kimmel@nih.gov or by phone at 301-443-6504 for further information.
    NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for access to biospecimens from the Adolescent Brain Cognitive Development (ABCD) Study, the largest longitudinal study of child health in the United States. This initiative, titled NIH Brain Development Cohorts (NBDC) Biospecimen Access, allows researchers to utilize biological samples such as blood, saliva, and hair to investigate the effects of environmental and biological factors on adolescent brain development and health. The program does not provide direct funding for research costs; applicants must secure their own funding and can apply for specific samples to enhance scientific understanding of adolescent health over a maximum project period of three years. Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by May 5, 2026.
    High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)" aimed at supporting research that informs the FDA's tobacco regulatory authorities. This initiative seeks applications for high-priority research projects that address topics such as addiction, behavior, health effects, product composition, and toxicity, with the goal of enhancing the scientific data available for tobacco product regulation. The total estimated funding for this program is $7 million, with an award ceiling of $500,000 and an expected eight awards to be made. Interested applicants can reach out to Erik Rodriquez, Ph.D., M.P.H., at TRSP@nih.gov or by phone at 301-827-2830, with applications due by May 4, 2026, and awards expected to be announced by December 4, 2026.
    Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing the upcoming Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), aimed at supporting high-priority research topics in tobacco regulatory science. This program seeks to fund innovative research that will provide scientific data to inform the FDA's regulatory authorities concerning tobacco products, particularly in relation to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). With an estimated total funding of $500,000 and the expectation of awarding four grants, the Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2025, with applications due in Winter 2026. For further inquiries, interested applicants can contact Erik Rodriquez, Ph.D., at TRSP@nih.gov or by phone at 301-827-2830.
    NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)." This initiative invites applications to leverage the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate integrated genetic and multi-omics data aimed at uncovering the molecular mechanisms underlying Heart, Lung, Blood, and Sleep (HLBS) disorders. The program is significant for advancing the understanding of genetic factors contributing to HLBS diseases, with a focus on transitioning from genetic associations to molecular insights, potentially utilizing artificial intelligence and machine learning tools. No direct funding will be provided; instead, successful applicants will gain access to omics assay resources and are expected to contribute data to public NIH-designated controlled-access databases. The application period opens on October 6, 2025, and closes on May 8, 2028, with a maximum project duration of three years. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) to support early-stage researchers in tobacco regulatory science. This funding opportunity aims to facilitate small-scale projects that generate data to inform the U.S. Food and Drug Administration's (FDA) regulations on tobacco products, in alignment with the Family Smoking Prevention and Tobacco Control Act (FSPTCA). Eligible applicants include various organizations such as higher education institutions, non-profits, and government entities, with awards of up to $75,000 available for projects lasting up to two years, and a total funding pool of $500,000 anticipated for fiscal year 2026. Interested applicants should submit their proposals through Grants.gov and eRA Commons by the closing date of July 14, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.
    Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)" aimed at supporting research projects that evaluate policies related to tobacco, alcohol, and cannabis use in the United States. The initiative focuses on understanding how these policies impact substance use and secondhand exposure among populations experiencing health disparities, with an emphasis on community engagement to enhance cancer prevention efforts. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding available up to $500,000 per year for a maximum of five years. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for January 7, 2028.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science, inviting R01 research applications that focus on biomedical and behavioral research to inform tobacco product regulation. This initiative aims to generate scientific data that will enhance public health protections related to tobacco use, with a particular emphasis on fostering diverse perspectives through a simplified peer review framework. The total estimated funding for this program is $4 million, with an award ceiling of $500,000 for each of the anticipated five awards, and the NOFO is expected to be published in Winter 2024, with applications due in Summer 2025. Interested applicants should prepare to submit new applications, as only new proposals will be considered, and further details will be available upon the official release of the NOFO.